# Phase 3 Esophageal Squamous Cell Carcinoma trials: 20 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 20 trials in phase 3 for Esophageal Squamous Cell Carcinoma that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 3 Esophageal Squamous Cell Carcinoma trials: 20 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-3/esophageal-squamous-cell-carcinoma

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 20
- Recruiting or not yet: 20
- Read on: November 19, 2026

## Trials

The 20 newest of 20, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 9, 2026 | NCT07924111 | A Randomized, Controlled, Double-Blind, Multicenter Phase III Clinical Trial to Evaluate the Efficacy and Safety of Enlonstobart, With or... | CSPC Megalith Biopharmaceutical Co.,Ltd. | Phase 3 | Not yet recruiting | Esophageal Squamous Cell Carcinoma | 585 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07924111) |
| June 5, 2026 | NCT07629817 | Surgery vs. Radical Chemoradiotherapy for Esophageal SCC After Neoadjuvant Immunochemotherapy | Henan Cancer Hospital | Phase 3 | Recruiting | Esophageal Squamous Cell Carcinoma | 1,044 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07629817) |
| June 2, 2026 | NCT07621601 | A Study of HS-20093 in Patients With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) | Hansoh BioMedical R&D Company | Phase 3 | Not yet recruiting | Esophageal Squamous Cell Carcinoma (ESCC) | 494 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07621601) |
| March 11, 2026 | NCT07463573 | QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma | Qilu Pharmaceutical Co., Ltd. | Phase 3 | Recruiting | Esophageal Squamous Cell Carcinoma (ESCC) | 466 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07463573) |
| November 24, 2025 | NCT07246330 | Stratified Treatment in Unresectable Locally Advanced ESCC Without Progression After Chemoimmunotherapy Induction Plus CCRT: Toripalimab... | Tianjin Medical University Cancer Institute and Hospital | Phase 3 | Recruiting | Esophageal Squamous Cell Carcinoma (ESCC) | 340 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07246330) |
| September 17, 2025 | NCT07177794 | Consolidation of Toripalimab and Capecitabine After Chemoradiotherapy in ESCC | Sun Yat-sen University | Phase 3 | Recruiting | Esophageal Cancer, Chemoradiotherapy | 242 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07177794) |
| May 1, 2025 | NCT06952621 | Neoadjuvant Treatment of Toripalimab Combined With Nab-paclitaxel and Platinum Versus Neoadjuvant Docetaxel Combined With Cisplatin and... | Tang-Du Hospital | Phase 3 | Not yet recruiting | Esophageal Squamous Cell Carcinoma (ESCC) | 390 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06952621) |
| October 16, 2024 | NCT06644781 | A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC)... | Daiichi Sankyo | Phase 3 | Recruiting | Esophageal Squamous Cell Carcinoma | 510 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06644781) |
| August 21, 2024 | NCT06563869 | Sintilimab With Chemotherapy Plus PEG-rhG-GSF for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma | The First Affiliated Hospital with Nanjing Medical University | Phase 3 | Recruiting | Esophageal Squamous Cell Carcinoma | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06563869) |
| July 15, 2024 | NCT06501664 | Liposomal Irinotecan and 5-FU as Second-line Therapy for Patients With ESCC | Sponsor not shown (see the record) | Phase 3 | Not yet recruiting | Esophageal Cancer | 360 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06501664) |
| January 8, 2024 | NCT06194734 | A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer | Beijing Konruns Pharmaceutical Co., Ltd. | Phase 3 | Recruiting | Esophageal Squamous Cell Carcinoma | 490 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06194734) |
| January 5, 2024 | NCT06190782 | Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor | Fudan University | Phase 3 | Recruiting | Esophageal Squamous Cell Carcinoma, Oligometastatic Disease, Radiotherapy | 354 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06190782) |
| June 26, 2023 | NCT05919030 | A Study of Chemoradiation in Combination with Tislelizumab As First Line Treatment in Participants with Advanced Esophageal Squamous Cell... | Renmin Hospital of Wuhan University | Phase 3 | Recruiting | Esophageal Squamous Cell Carcinoma | 155 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05919030) |
| August 10, 2022 | NCT05495152 | Adjuvant Sintilimab for Locally Advanced Esophageal Squamous Cell Carcinoma | Henan Cancer Hospital | Phase 3 | Recruiting | Esophageal Squamous Cell Carcinoma | 219 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05495152) |
| May 3, 2022 | NCT05357846 | PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101) | Sun Yat-sen University | Phase 3 | Recruiting | Squamous Cell Esophageal Carcinoma, Esophageal Cancer, Oesophageal Cancer | 422 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05357846) |
| February 17, 2022 | NCT05244798 | Sintilimab Plus NCT or NCRT Versus NCRT for ESCC | Sichuan Cancer Hospital and Research Institute | Phase 3 | Not yet recruiting | Esophageal Squamous Cell Carcinoma | 420 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05244798) |
| March 19, 2021 | NCT04807673 | Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002) | Tianjin Medical University Cancer Institute and Hospital | Phase 3 | Recruiting | Esophageal Squamous Cell Carcinoma | 342 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04807673) |
| July 7, 2020 | NCT04460352 | Chemoradiotherapy Followed by Planned Surgery or by Surveillance and Surgery Only When Needed for Oesophageal Cancer | Karolinska University Hospital | Phase 3 | Recruiting | Esophageal Squamous Cell Carcinoma | 1,020 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04460352) |
| April 1, 2020 | NCT04328948 | A Randomized Controlled Trial Evaluating of Prophylactic Irradiation in CRT for cT1bN0M0 ESCC | National Cancer Center, Japan | Phase 3 | Recruiting | Esophageal Squamous Cell Carcinoma | 280 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04328948) |
| October 24, 2019 | NCT04138212 | Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Resectable Locally Advanced Esophageal Cancer (HCHTOG1903) | Henan Cancer Hospital | Phase 3 | Recruiting | Esophageal Squamous Cell Carcinoma | 456 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04138212) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Henan Cancer Hospital | 3 |
| Sun Yat-sen University | 2 |
| Tianjin Medical University Cancer Institute and Hospital | 2 |
| Renmin Hospital of Wuhan University | 1 |
| Tang-Du Hospital | 1 |
| [Qilu Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/qilu-pharmaceutical-co-ltd) | 1 |
| The First Affiliated Hospital with Nanjing Medical University | 1 |
| Fudan University | 1 |
| [Hansoh BioMedical R&D Company](https://specstream.ai/data/clinical-trials/company/hansoh-biomedical-r-and-d-company) | 1 |
| Karolinska University Hospital | 1 |
| National Cancer Center, Japan | 1 |
| [Daiichi Sankyo](https://specstream.ai/data/clinical-trials/company/daiichi-sankyo) | 1 |
| Sichuan Cancer Hospital and Research Institute | 1 |
| [CSPC Megalith Biopharmaceutical Co.,Ltd.](https://specstream.ai/data/clinical-trials/company/cspc-megalith-biopharmaceutical-co-ltd) | 1 |
| Beijing Konruns Pharmaceutical Co., Ltd. | 1 |

## By country

| Country | Trials |
| --- | --- |
| China | 15 |
| Norway | 2 |
| Sweden | 2 |
| Taiwan | 2 |
| Japan | 2 |
| Canada | 1 |
| Ireland | 1 |
| Belgium | 1 |
| Denmark | 1 |
| France | 1 |
| Germany | 1 |
| Italy | 1 |
| Netherlands | 1 |
| Poland | 1 |
| Romania | 1 |
| South Korea | 1 |
| Spain | 1 |
| United Kingdom | 1 |
| United States | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pediatric anesthesiology practices in the United States](https://specstream.ai/data/businesses/pediatric-anesthesiology-practices/united-states)
- [Pubs in the United States](https://specstream.ai/data/businesses/pubs/united-states)
- [Specialty hospitals in the United States](https://specstream.ai/data/businesses/specialty-hospitals/united-states)
- [Turkish restaurants in the United States](https://specstream.ai/data/businesses/turkish-restaurants/united-states)
- [Agricultural services in the United States](https://specstream.ai/data/businesses/agricultural-services/united-states)
- [B2B science and technology companies in the United States](https://specstream.ai/data/businesses/b2b-science-and-technology-companies/united-states)
